Philips EchoNavigator 4.0 Image-Guided Solution for Structural Heart Interventions Launched in International Markets

May 16, 2022—Royal Philips announced the international launch of EchoNavigator 4.0 at the EuroPCR 2022 conference, held May 17-20 in Paris, France. EchoNavigator 4.0 is the latest generation of the company’s advanced image-guided therapy solution for the treatment of structural heart disease. Philips EchoNavigator 4.0 is not yet available in all markets, including the United States and China, advised the company.

According to the company, EchoNavigator 4.0 gives users of Philips’ Epiq CVxi interventional cardiology ultrasound system greater control of live fusion-imaging on Philips’ Azurion image-guided therapy platform.

EchoNavigator 4.0 helps interventional teams to decide, guide, treat, and confirm complex structural heart disease therapy, such as heart valve repair or replacement.

The company noted that the device integrates real-time transesophageal echocardiography, which places the ultrasound transducer close to the heart, and x-ray fluoroscopy. The solution also includes

• Extended anatomic intelligence models
• Transseptal puncture guidance to help access the left atrium and mitral valve from the right atrium
• Three-dimensional (3D) live-image fusion capabilities, including Philips’ TrueVue photo-realistic rendering and GlassVue volumetric imaging modes
• Automatic selection of an appropriate set of multiplanar reconstruction planes, with presets for common views of the aortic and mitral valves and left atrial appendage.

“The latest EchoNavigator release gives us unique peri-interventional possibilities by offering a comprehensive set of automated views based on advanced 3D heart models in combination with live fusion imaging,” commented Patric Biaggi, MD, in the company’s press release. “This allows us to treat our patients with greater confidence and precision during every stage of the procedure.” Dr. Biaggi is Head of Cardiac Imaging at Heart Clinic Hirslanden in Zurich, Switzerland.